During the past decade, Infectious Diseases Research Center conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 5 clinical trials were completed, i.e. on average, 55.6% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Infectious Diseases Research Center" #1 sponsor was "Indiana University" with 7 trials, followed by "Genocea Biosciences, Inc." with 3 trials sponsored, "Gilead Sciences" with 2 trials sponsored, "Vical" with 2 trials sponsored and "Graceway Pharmaceuticals, LLC" with 2 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Infectious Diseases Research Center" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 2 trials as a collaborator, "National Institute of Mental Health (NIMH)" with 1 trials as a collaborator and "Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Infectious Diseases Research Center" are "Genital Herpes Simplex Type 2" (4 trials), "HIV" (2 trials), "HIV Infections" (2 trials), "HIV/AIDS" (2 trials) and "Insomnia" (2 trials). Many other conditions were trialed in "Infectious Diseases Research Center" in a lesser frequency.

Most popular intervention types in "Infectious Diseases Research Center" are "Drug" (6 trials), "Biological" (5 trials), "Behavioral" (3 trials), "Other" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "GEN-003 Vaccine (30μg of each antigen)" (2 trials), "GEN-003 Vaccine (60μg of each antigen)" (2 trials), "Matrix-M2 Adjuvant (25μg)" (2 trials) and "Matrix-M2 Adjuvant (50μg)" (2 trials). Other intervention names were less common.

The vast majority of trials in "Infectious Diseases Research Center" are 16 trials for "All" genders.

Currently, there are NaN active trials in "Infectious Diseases Research Center". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Infectious Diseases Research Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Infectious Diseases Research Center, 3 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".